These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31534310)

  • 41. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
    Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
    Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.
    Singh AD; Maitra S; Singh N; Tyagi P; Ashraf A; Kumar R; Shalimar
    Aliment Pharmacol Ther; 2020 Mar; 51(5):490-504. PubMed ID: 31943236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
    Shah R; Barclay ST; Peters ES; Fox R; Gunson R; Bradley-Stewart A; Shepherd SJ; MacLean A; Tong L; van Vliet VJE; Ngan Chiu Bong M; Filipe A; Thomson EC; Davis C
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection
    Matthew AN; Kurt Yilmaz N; Schiffer CA
    Biochemistry; 2018 Feb; 57(5):481-482. PubMed ID: 29192768
    [No Abstract]   [Full Text] [Related]  

  • 48. Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review.
    Volpicelli L; Biliotti E; Milito C; Cruciata A; Spaziante M; Rivano Capparuccia M; Taliani G; Mezzaroma I
    Infez Med; 2020 Dec; 28(4):616-620. PubMed ID: 33257639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
    Wang CY; Liu J; Wen J; Ma HX; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1194-1195. PubMed ID: 35045636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir.
    Quintero García D; Sebastián Cuevas FJ; Crehuá Gaudiza E
    Rev Esp Enferm Dig; 2021 Feb; 113(2):150-151. PubMed ID: 33207896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).
    Cornberg M; Stoehr A; Naumann U; Teuber G; Klinker H; Lutz T; Möller H; Hidde D; Lohmann K; Simon KG
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
    Park YJ; Woo HY; Heo J; Park SG; Hong YM; Yoon KT; Kim DU; Kim GH; Kim HH; Song GA; Cho M
    Gut Liver; 2021 May; 15(3):440-450. PubMed ID: 32839365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.
    de Salazar A; Dietz J; di Maio VC; Vermehren J; Paolucci S; Müllhaupt B; Coppola N; Cabezas J; Stauber RE; Puoti M; Arenas Ruiz Tapiador JI; Graf C; Aragri M; Jimenez M; Callegaro A; Pascasio Acevedo JM; Macias Rodriguez MA; Rosales Zabal JM; Micheli V; Garcia Del Toro M; Téllez F; García F; Sarrazin C; Ceccherini-Silberstein F;
    J Antimicrob Chemother; 2020 Nov; 75(11):3349-3358. PubMed ID: 32772078
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    Dietz J; Sarrazin C
    J Hepatol; 2021 Jul; 75(1):254-255. PubMed ID: 33892009
    [No Abstract]   [Full Text] [Related]  

  • 57. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Turnes J; Rincón D; Calleja JL; Delgado MB; Rosales JM; Andrade RJ; Manzano ML; Salmerón FJ; López MA; Calvo M; Gómez J; Molina E; Frias YN; Gálvez-Fernández RM; Vallejo-Senra N; París S; Santos de Lamadrid R; Olveira A
    Gastroenterol Hepatol; 2022 May; 45(5):342-349. PubMed ID: 34129903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    Martin MT; Patel S; Kulik L; Chan C
    J Hepatol; 2021 Jul; 75(1):251-254. PubMed ID: 33652031
    [No Abstract]   [Full Text] [Related]  

  • 59. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
    Hara T; Ohara T; Taniguchi M; Sakai H; Oka K; Iwai N; Tsuji T; Okuda T; Nagata A; Komaki T; Sakagami J; Kagawa K
    Intern Med; 2021 Aug; 60(15):2437-2443. PubMed ID: 33612683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
    Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
    Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.